指南与共识血管炎

儿童重症ANCA相关性血管炎共识治疗方案

Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2022-06-01

针对儿童ANCA相关性血管炎缺乏标准化治疗的问题,CARRA工作组通过文献回顾和名义群体共识会议,制定了重症儿童AAV的诱导缓解和维持缓解共识治疗方案(CTP),并定义了糖皮质激素减量方案、核心数据集和结局指标;CARRA成员投票接受率分别为94%和98%。

要点

  • CARRA制定重症儿童AAV诱导和维持缓解各2个CTP。
  • 目标人群为<18岁新发GPA、MPA或肾局限性AAV重症患者。
  • CTP获CARRA成员投票接受率诱导94%、维持98%。

核心结论

  • 共识方法建立了儿童重症AAV的标准化CTP,原则上获CARRA全体成员接受,用于长期注册研究中的实用性比较效果评价。

研究设计与样本

  • CARRA风湿科和肾内科成员组成AAV工作组,进行文献回顾后采用名义群体技术召开面对面共识会议。
  • 目标人群为<18岁新发肉芽肿性多血管炎(GPA)、显微镜下多血管炎或肾局限性AAV的重症患者,排除嗜酸性GPA。

主要发现

  • 工作组为重症AAV的诱导缓解和维持缓解各制定2个CTP,并定义糖皮质激素减量方案、核心数据集和结局指标。
  • CARRA成员随机样本投票接受CTP,诱导缓解批准率94%(75/80),维持缓解批准率98%(78/80)。

关键数值与推荐

  • 诱导缓解CTP获94%(75/80)批准,维持缓解CTP获98%(78/80)批准。

临床怎么用

  • 该CTP可用于儿童重症AAV的标准化治疗,并支持在长期注册研究中评估比较效果和安全性。

局限性

  • 儿童AAV罕见,随机试验不可行,CTP基于共识而非随机对照证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is no standardized approach to the treatment of pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Because of the rarity of pediatric AAV, randomized trials have not been feasible. The present study of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) was undertaken to establish consensus treatment plans (CTPs) for severe pediatric AAV to enable the future study of comparative effectiveness and safety. METHODS: A workgroup of CARRA members (rheumatologists and nephrologists) formed the AAV Workgroup. This group performed a literature review on existing evidence-based treatments and guidelines for the management of AAV. They determined that the target population for CTP development was patients <18 years of age with new-onset granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or renal-limited AAV (eosinophilic GPA was excluded), with presentation confined to those with severe disease (i.e., organ- or life-threatening). Face-to-face consensus conferences employed nominal group techniques to identify treatment strategies for remission induction and remission maintenance, data elements to be systematically collected, and outcomes to be measured over time. RESULTS: The pediatric AAV Workgroup developed 2 CTPs for each of the remission induction and remission maintenance of severe AAV. A glucocorticoid-weaning regimen for induction and maintenance, a core data set, and outcome measures were also defined. A random sample of CARRA membership voted acceptance of the CTPs for remission induction and remission maintenance, with a 94% (75 of 80) and 98% (78 of 80) approval rate, respectively. CONCLUSION: Consensus methodology established standardized CTPs for treating severe pediatric AAV. These CTPs were in principle accepted by CARRA-wide membership for the evaluation of pragmatic comparative effectiveness in a long-term registry.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Morishita KA, Wagner-Weiner L, Yen EY, et al. Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2022. PMID: 33675161. doi:10.1002/acr.24590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。